Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
Volition (NYSE: VNRX) announced new laboratory partnerships to expand access to its Nu.Q® Vet Cancer test in the U.S. and Asia. Midwest Veterinary Laboratory will offer the test across all 50 U.S. states beginning February 2026. Bioguard will offer the test via its Animal Health Diagnostic Center, described as the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. Management highlighted integrating Nu.Q® into annual or senior wellness exams to enable earlier cancer detection in dogs. Volition cited a Total Addressable Market for canine screening of about $100 million for the U.S., Europe and Japan, rising to just under $150 million with China.
VolitionRx (NYSE AMERICAN: VNRX) is sponsoring an industry symposium at the Veterinary Meeting and Expo (VMX) in Orlando, Florida, with a presentation on Monday, January 19, 2026 at 2:45 PM EST by Dr. Sue Ettinger titled "Utilizing the Nu.Q® Vet Cancer Test in Practice."
The company said its Volition Veterinary Diagnostics Development team will staff booth 2243 during the conference, which draws about 20,000 veterinary professionals. Management highlighted using the Nu.Q® Canine Cancer Test during annual or senior-wellness exams to aid earlier cancer detection and support timely care decisions for pet owners.
Volition (NYSE AMERICAN: VNRX) entered an amended and restated securities purchase agreement with Lind Global Asset Management XII LLC to receive $2.0 million gross proceeds in exchange for a senior secured convertible promissory note with $2.4 million principal (the 2026 Note) and a five-year warrant to buy 7,000,350 common shares at $0.5714 per share. The company will pay a $70,000 commitment fee by deduction from the funding. The 2026 Note accrues no interest and is repayable in 18 monthly installments of $133,333, convertible at $0.5714, and the company must file a resale registration within 30 days of closing.
Volition (NYSE AMERICAN: VNRX) reported clinical study results for the Nu.Q® Vet Feline assay showing 100% specificity and detection of over 80% of feline lymphomas, supporting development of a blood-based liquid biopsy for cats. The company cites a U.S. population of 73.8 million pet cats, ~1-in-5 cats estimated to develop cancer, >18 million senior cats (8+), and a North American veterinary oncology market projected at $1.77 billion by 2025. Management expects a peer-reviewed publication, a $5 million contractual milestone, and commercial rollout via existing lab and point-of-care channels.
Volition (NYSE AMERICAN: VNRX) issued its Business Review 2025 outlining commercial, clinical, and IP milestones as it commercializes the Nu.Q platform.
Key points: first clinical order for the Nu.Q Cancer assays for lung cancer, inclusion of the Nu.Q NETs assay in a government-backed ~$7.3 million French sepsis evaluation, first revenue from the CE‑Marked Nu.Q NETs automated assay, signed human‑licensing agreements with Werfen and Hologic, and a payable $5 million contractual milestone tied to feline lymphoma results.
Scientific advances highlighted include Capture-Seq™ with 180-fold (18,000%) ultrashort DNA enrichment and peer‑reviewed NETs data (1,713 patients) supporting clinical utility.
Volition (NYSE: VNRX) announced a preprint describing Capture-Seq™, a method that physically enriches ultrashort transcription factor–bound cfDNA for liquid biopsy. The company reports a 180-fold (18,000%) enrichment, removal of ~99% background DNA, and two patent-pending separation technologies. In a small training cohort of 70 subjects (49 cancer patients), analysis reportedly achieved 100% sensitivity and 100% specificity. Volition projects a $23 billion annual TAM and is seeking commercial partners; results require independent validation in larger studies.
Volition (NYSE AMERICAN: VNRX) presented two abstracts at the North America Conference on Lung Cancer in Chicago reporting clinical data for its Nu.Q® Cancer assays. The studies found that circulating H3K27Me3-nucleosome levels rise with disease stage and that baseline levels at diagnosis act as an independent prognostic biomarker for overall survival, including in ctDNA-negative patients.
One poster described pre-operative H3K27Me3 measurements that stratify non-small cell lung cancer patients by recurrence-free and overall survival and may flag micro-metastatic disease to guide systemic-therapy decisions. The reports note an initial hospital order to complete internal certification ahead of clinical use, and Volition said it is progressing toward first clinical deployment of Nu.Q® Cancer.
Volition (NYSE AMERICAN: VNRX) announced that its Nu.Q® NETs H3.1 assay has been included as the sole biomarker in DETECSEPS, a French real-world program for early detection of sepsis funded under France 2030.
The DETECSEPS consortium received approximately €6.3 million (~$7.3 million) in government financing. Results cited show H3.1 accurately distinguishes sepsis from non-infectious inflammation, correlates with disease severity, and outperforms APACHE II and SOFA for ICU admission prognostic power. H3.1 can be run on the IDS i10® analyzer with results within one hour. The release highlights a potential national rollout and cites ~166 million annual sepsis cases as a large testing opportunity.
VolitionRx (NYSE AMERICAN: VNRX) announced the first commercial sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon in Lyon, France on November 25, 2025.
The order is to complete internal clinical certification ahead of introducing Nu.Q® into routine clinical practice for cancer management, with cited evidence that methylated nucleosome biomarkers at non‑small cell lung cancer (NSCLC) diagnosis correlate with survival and progression‑free survival and can help identify patients who may benefit from curative care.
Company executives described the sale as a commercialization milestone and a step toward clinical use and licensing of Nu.Q® in human cancer.
VolitionRx (NYSE AMERICAN: VNRX) reported third quarter 2025 results and a business update on November 13, 2025, and will host an earnings call on November 14, 2025 at 8:30 a.m. ET.
Key financials: Q3 revenue was $0.6 million (+32% YoY). Operating expenses were down 10% year‑over‑year for the quarter and 18% for the first nine months. Net loss decreased 8% for Q3 and 20% year‑to‑date. Net cash used in operations was $3.6 million in the quarter, down 33% YoY. Post‑quarter, the company received approximately $6.1 million net proceeds from a public offering.
Management highlighted new human agreements with Werfen (APS) and a co‑marketing/services deal with Hologic, ongoing discussions with ~10 diagnostics/liquid‑biopsy firms, and forthcoming peer‑reviewed publications including Capture‑Seq™ developments.